nach oben

Comprehensive Therapy

Erschienen in:

01.06.2007 | Original Article

Alzheimer’s Disease

verfasst von: Richard J. Goldberg

Erschienen in: Comprehensive Therapy | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Alzheimer’s disease is the most prevalent form of dementia. There are significant efforts underway to elucidate the pathogenesis of this disease and to find ways to lessen the impact of the symptoms. This paper summarizes current knowledge regarding the diagnosis and treatment of the disorder.

Hardy J, Selkoe D. The amloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353–6.PubMedCrossRef

Riekse R, Leverenz J, McCormick W. Effect of vascular lesions on cognition in Alzheimer’s disease: a community-based study. J Am Geriatr Soc 2004;52:1442–48.PubMedCrossRef

Small G, Rabins P, Barry P. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. J Am Med Assoc 1997;278:1363–71.CrossRef

Knopman D, DeKosky S, Cummings J. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–53.PubMed

Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.PubMedCrossRef

Snowdon D, Greiner L, Mortimer J, Riley K, Greiner P, Markesbery W. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. J Am Med Assoc 1997;277:813–7.CrossRef

Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–75.CrossRef

Lim A, Tsuang D, Kukull W. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999;47:564–9.PubMed

Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–13.PubMedCrossRef

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–34.PubMedCrossRef

Harvey R, Skelton-Robinson M, Rossor M. The prevalence and causes of dementia in people under age 65 years. J Neurol Neurosurg Psychiatry 2003;74:1206–9.PubMedCrossRef

Farrer L, Cupples L, Haines J. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J Am Med Assoc 1997;278:1349–56.CrossRef

Raber J, Huang Y, Ashford J. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641–50.PubMedCrossRef

Meyer M, Tschanz J, Norton M. ApoE genotype predicts when-not whether-one is predisposed to develop Alzheimer’s disease. Nat Genet 1998;19:321–2.PubMedCrossRef

Tariot P, Solomon P, Morris J. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76.PubMed

Feldman H, Gauthier S, Hecker J. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–20.PubMed

Rosler M, Retz W, Retz-Junginger P. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioral symptoms in Alzheimer’ disease. Behav Neurol 1998;11:211–6.PubMed

Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer’s disease. Am J Psychiatr 1984;141:1356–64.PubMed

Francis P, Palmer A, Snape M. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47.PubMedCrossRef

Cummings J. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131–45.PubMedCrossRef

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1:CD005593.

AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized double-blind trial. Lancet 2004;363:2105–15.CrossRef

Bullock R, Touchon J, Bergman H. Rivastigimine and donezepil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21:1317–27.PubMedCrossRef

Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59:817–22.PubMedCrossRef

Geldmacher D, Provenzano G, McRae T. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003;51:937–44.PubMedCrossRef

Sano M, Wilcock G, Van Baelen B. The effects of galantamine treatment on caregiver time in Alzheimer’s disease. Int J Geriatr Psychiatry 2003;18:942–50.PubMedCrossRef

Galasko D, Kershaw P, Schneider L. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer’s disease. J Am Geriatr Soc 2004;52:1070–6.PubMedCrossRef

Mohs R, Doody R, Morris J. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481–8.PubMed

Potkin S, Anand R, Hartman R. Impact of Alzheimer’s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuro-Psychopharmacol Biol Psychiatry 2002;26:713–20.CrossRef

Doody R, Stevens J, Beck C. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–66.PubMed

Reisberg B, Doody R, Stoffler A. Memantine in moderate-to-severe Alzheimers disease. N Engl J Med 2003;348:1333–41.PubMedCrossRef

Areosa S, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005;3:CD003154.

Tariot P, Farlow M, Grossberg G. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J Am Med Assoc 2004;291:317–24.CrossRef

Morris M, Beckett L, Pa S. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:121–6.PubMedCrossRef

Sano M, Ernesto C, Thomas R. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216–22.PubMedCrossRef

Petersen R, Thomas R, Grundman M. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–88.PubMedCrossRef

Wolozin B, Brown Jr, Theisler C. The cellular biochemistry of cholesterol and statins: insights in the pathophysiology and therapy of Alzheimer’s disease. CNS Drug Rev 2004;10:127–46.PubMedCrossRef

Rea T, Breitner J, Psaty B. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047–51.PubMedCrossRef

Zandi P, Sparks D, Khachaturian A. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217–24.PubMedCrossRef

Mulnard R, Cotman C, Kawas C. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. J Am Med Assoc 2000;283:1007–15.CrossRef

Shumaker S, Legault C, Kuller L. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women: Women’s Health Initiative Memory Study. J Am Med Assoc 2004;291:2947–58.CrossRef

Kanowski S, Hoerr R. Ginko biloba extract Egb 761 dementia: intent-to-treat analyses of a 24 week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.PubMedCrossRef

Aisen P, Schafer K, Grundman M. Alzheimer’s Disease Cooperative Study: effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 2003;289:2819–26.CrossRef

Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599–606.PubMedCrossRef

Orgogozo J, Gilman S, Dartigues J. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46–54.PubMed

Geerts H. NC-531 (Neurochem). Curr Opin Investig Drugs 2004;5:95–100.PubMed

Cherny R, Atwood C, Xilinas M. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001;30:665–76.PubMedCrossRef

Titel: Alzheimer’s Disease
verfasst von: Richard J. Goldberg
Publikationsdatum: 01.06.2007
Verlag: Humana Press Inc
Erschienen in: Comprehensive Therapy / Ausgabe 2/2007
Print ISSN: 0098-8243
Elektronische ISSN: 1559-1190
DOI: https://doi.org/10.1007/s12019-007-8000-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Alzheimer’s Disease

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Alkaptonuria Presenting with Conjunctival Lesion

Cardiovascular Manifestations Seen in Obstructive Sleep Apnea

Submicrobial Doxycycline and Rosacea

CME Questions

Hepatitis C: Epidemiology, Diagnosis, and Management

Book Reviews